Dr. Reddy’s Laboratories Ltd. announced the launch of Linaclotide, a first-in-class guanylate cyclase-C (GC-C) agonist for adults suffering from chronic constipation in India. Dr. Reddy’s becomes the first pharmaceutical company to receive regulatory approval to launch Linaclotide in India under the brand name Colozo®, available in 72 mcg and 145 mcg strengths.
Linaclotide is a USFDA-approved medication indicated for adults suffering from chronic idiopathic constipation (CIC), irritable bowel syndrome with constipation (IBS-C) in adults, and functional constipation (FC) in paediatric patients aged 6 to 17 years. It is a highly selective agonist of guanylate cyclase-C (GC-C) receptors in the intestine. In India, Linaclotide is approved for the treatment of Chronic Idiopathic Constipation (CIC) in adults.
M.V. Ramana, Chief Executive Officer, Branded Markets (India and Emerging Markets), Dr. Reddy’s, said: “The launch of Colozo® marks a significant step in our gastrointestinal segment in India and adds to our list of novel and first-in-class drugs after the launch of BixiBat® in India last year. Colozo® is a differentiated, USFDA-approved solution for Chronic Constipation. Backed by robust clinical evidence and promising outcomes, Colozo® represents a breakthrough in addressing unmet needs of patients and enhancing their quality of life. With Colozo®, we continue to strengthen our commitment to deliver advanced therapies that meaningfully improve everyday patient care, in keeping with our goal to serve 1.5 bn patients by 2030.”
